Critical Reviews in Oncology / Hematology
Volume 81, Issue 2 , Pages 136-150 , February 2012

Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors

  • Arlene Chan

      Affiliations

    • Mount Medical Centre, 41, 146 Mounts Bay Rd, Perth, Western Australia 6000, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 618 94814522; fax: +61 618 94814544.
    • ,
  • Shailendra Verma

      Affiliations

    • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
    • ,
  • Sibylle Loibl

      Affiliations

    • German Breast Group, Neu-Isenburg, Germany
    • ,
  • Jeffrey Crawford

      Affiliations

    • Duke University Medical Center, Durham, NC, USA
    • ,
  • Mi Rim Choi

      Affiliations

    • Amgen Inc., Thousand Oaks, CA, USA
    • ,
  • Lyndah Dreiling

      Affiliations

    • Amgen Inc., Thousand Oaks, CA, USA
    • ,
  • Ted Vandenberg

      Affiliations

    • University of Western Ontario, London, ON, Canada

,Accepted 11 March 2011.

References 

  1. National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 2.2010. March 13, 2010. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [accessed 02.04.10].
  2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–1144
  3. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205
  4. AGO Guidelines. English version 10.1.0. February 2010. Available at: http://www.ago-online.de/index.php?lang=en&site=mamma_guide_topical&topic=mamma_guide [accessed 07.06.10].
  5. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313
  6. von Minckwitz G, Kummel S, du Bois A, et al. Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292–298
  7. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210–5217
  8. Arango BA, Castrellon AB, Santos ES, Raez LE. Second-line therapy for non-small-cell lung cancer. Clin Lung Cancer. 2009;10:91–98
  9. Roy V, Perez EA. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Res Treat. 2009;116:31–38
  10. Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol. 2009;21:381–385
  11. Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550
  12. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810–1816
  13. Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol. 2007;25:5777–5784
  14. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525–1531
  15. Herceptin® (trastuzumab) prescribing information. South San Francisco, CA: Genentech, Inc.; March 2009;Available at: http://www.herceptin.com [accessed 02.04.10]
  16. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–4274
  17. Capri G, Chang J, Chen SC, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol. 2010;21:474–480
  18. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26:5544–5552
  19. Von Minckwitz G, Eidtmann H, Loibl S, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GerparQuinto trial. Annal Oncol. 2011;22:301–306
  20. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330:217
  21. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524–4531
  22. National Comprehensive Cancer Network. Myeloid Growth Factors: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 1.2010. December 7, 2009. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive [accessed 02.04.10].
  23. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–2453
  24. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2009;20(4S):162–165
  25. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007;25:3699–3704
  26. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-Year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27:1177–1183
  27. Chan A, Fu W, Shih V, Coyuco J, Tan S, Ng R. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer. 2011;19:497–504
  28. Meyers R, Meyers J, Rajagopal S, et al. Chemotherapy induced febrile neutropenia (FNE) from docetaxel with cyclophosphamide (TC) for adjuvant therapy of breast cancer in the community: reality check. In: Presented at the 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX; December 10–14. 2009;[abstract #2092]
  29. Vandenberg T, Younus J, Al-Khayyat S. Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice – a retrospective analysis. Curr Oncol. 2010;17:2–3
  30. Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol. 2006;17:1205–1212
  31. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24:5664–5671
  32. Alkhayyat S, Dent S, Verreault J, et al. Incidence of febrile neutropenia with taxane-based systemic therapy in women with early stage breast cancer [abstract]. Cancer Res. 2009;69(24S):2087
  33. Janni J, Sommer H, Rack B, et al. The ADEBAR trial: final toxicity analysis of a phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement. J Clin Oncol. 2007;25(18S):585
  34. Janni W, Harbeck N, Sommer H, et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel is equieffective, but less toxic than FEC120 in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. In: Presented at the 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX; December 9–13. 2009;[abstract #604]
  35. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26:3950–3957
  36. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–1439
  37. Untch M, Mobus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009;27:2938–2945
  38. Loibl S, von Minckwitz G, Harbeck N, et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res. 2008;10:R77
  39. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27:3611–3619
  40. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–7803
  41. Avastin® (bevacizumab) prescribing information. South San Francisco, CA: Genentech, Inc.; February 2004;Available at: http://www.fda.gov [accessed 02.04.10]
  42. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–3247
  43. Robert N, Dieras V, Glapsy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). In: Presented at the 45th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL; May 29–June 2. 2009;[abstract #1005]
  44. Avastin® (bevacizumab) prescribing information. South San Francisco, CA: Genentech, Inc.; July 2009;Available at: http://www.avastin.com [accessed 02.04.10]
  45. Avastin® (bevacizumab) summary of product characteristics. Grenzach-Wyhlen, Germany: Roche Pharma AG; September 2009;Available at: http://www.ema.europa.eu/humandocs/Humans/EPAR/avastin/avastin.htm [accessed 02.04.10]
  46. O'Shaughnessy J, Osborne C, Pippen JE, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: results of a randomized phase II trial [abstract]. J Clin Oncol. 2009;27(18S):3
  47. O'Shaughnessy J, Osborne C, Pippen JE, et al. Updated results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a PARP inhibitor, in combination with gemcitabine/carboplatin in metastatic triple-negatibe breast cancer. In: Presented at the 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX; December 9–13. 2009;[abstract #3122]
  48. Nexavar® (sorafenib) prescribing information. West Haven, CT: Bayer HealthCare Pharmaceuticals Inc.; February 2009;Available at: http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf [accessed 07.05.10]
  49. Nexavar® (sorafenib) summary of product characteristics. Berllin, Germany: Bayer Schering Pharma AG; December 2009;Available at: http://www.ema.europa.eu/humandocs/Humans/EPAR/nexavar/nexavar.htm [accessed 17.05.10]
  50. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109
  51. Bianchi G, Loibl S, Zamagni C, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009;20:616–624
  52. Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2009;27:11–15
  53. Baselga J Grupo Español de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos, Roché H, et al. SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer [abstract]. Cancer Res. 2009;69(24S):45
  54. Gradishar W, Kaklamani V, Prasad Sahoo T, et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib in combination with paclitaxel as a first-line therapy in patients with locally recurrent or metastatic breast cancer [abstract]. Cancer Res. 2009;69(24S):44
  55. Kubota K, Kawahara M, Ogawara M, et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol. 2008;9:1135–1142
  56. Haller DG, Rothenberg ML, Wong AO, et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol. 2008;26:4544–4550
  57. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842–1847
  58. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–1544
  59. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–4707
  60. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–3590
  61. Audeh M, Penson R, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer [abstract]. J Clin Oncol. 2009;27(15S):5500
  62. Freedman O, Zimmermann C, Clemons M. Interpreting the results of clinical trials of cancer chemotherapy: the importance of reporting concurrent supportive care. In: Presented at the 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX; December 10–14. 2008;[abstract #6138]
  63. Duff J, Leather J, Walden E, LaPlant K, George T. Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. In: Presented at the 45th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL; May 29–June 2. 2009;[abstract #6536]
  64. Dale DC, McCarter GC, Crawford J, Lyman GH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Cancer Netw. 2003;1:440–454

PII: S1040-8428(11)00070-9

doi: 10.1016/j.critrevonc.2011.03.003

Critical Reviews in Oncology / Hematology
Volume 81, Issue 2 , Pages 136-150 , February 2012

Article Tools

* Image Usage & Resolution